No full text
Article (Scientific journals)
Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study.
Dahlof, C.; Diener, H. C.; Goadsby, P. J. et al.
1998In European Journal of Neurology, 5 (6), p. 535-543
Peer Reviewed verified by ORBi
 

Files


Full Text
No document available.

Send to



Details



Abstract :
[en] Zolmitriptan is a selective 5-HT1B/1D receptor agonist for acute oral migraine therapy. This randomized, placebo-controlled, parallel-group study investigated the efficacy and tolerability of oral zolmitriptan (5, 10, 15 and 20 mg) in the treatment of single acute migraine attacks. Of 1181 patients randomized, 840 were evaluable for the primary efficacy analysis. Headache response rates (a reduction in headache intensity from severe or moderate at baseline to mild or no pain at 2 hours post-treatment) were similar across the zolmitriptan dose groups (66%, 71%, 69% and 77% for 5 mg, 10 mg, 15 mg and 20 mg, respectively) and were significantly higher than that for placebo (19%; all groups P < 0.001). A headache response was reported at 1 hour by 40-50% of zolmitriptan recipients (16% placebo). At 2 hours post dose, 39-47% of zolmitriptan-treated patients were pain-free, compared with 1% of placebo recipients. Headache recurrence occurred in 21-29% (upper 95% CI 37.1) of zolmitriptan-treated patients and in 65% (95% CI 38.3, 85.8) of placebo recipients. Zolmitriptan was well tolerated at each dose. The most commonly reported adverse events were asthenia, dizziness, paraesthesia and feelings of heaviness. Most adverse events were of mild or moderate intensity and were transient. The frequency of adverse events was dose-related. Although, zolmitriptan 5 mg exhibited the most favourable efficacy and tolerability profile, the dose response data suggest that lower doses would also offer significant efficacy. Copyright 1998 Lippincott Williams & Wilkins
Disciplines :
Neurosciences & behavior
Neurology
Author, co-author :
Dahlof, C.
Diener, H. C.
Goadsby, P. J.
Massiou, H.
Olesen, J.
Schoenen, Jean  ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie
Wilkinson, M.
Sweet, R. M.
Klein, K. B.
Language :
English
Title :
Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study.
Publication date :
1998
Journal title :
European Journal of Neurology
ISSN :
1351-5101
eISSN :
1468-1331
Publisher :
Blackwell Science, Oxford, United Kingdom
Volume :
5
Issue :
6
Pages :
535-543
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 29 September 2009

Statistics


Number of views
93 (1 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
59
Scopus citations®
without self-citations
44
OpenCitations
 
38

Bibliography


Similar publications



Contact ORBi